Chemotherapeutic Potential of Diazeniumdiolate-based Aspirin Prodrugs in Breast Cancer

Overview

Journal Free Radic Biol Med

Specialties Biochemistry
Biology
General Medicine

Date 2015 Feb 10

PMID 25659932

Citations 9

Authors

Debashree Basudhar

Robert C Cheng

Gaurav Bharadwaj

Lisa A Ridnour

David A Wink

Katrina M Miranda

Affiliations

Soon will be listed here.

Abstract

Diazeniumdiolate-based aspirin prodrugs have previously been shown to retain the anti-inflammatory properties of aspirin while protecting against the common side effect of stomach ulceration. Initial analysis of two new prodrugs of aspirin that also release either nitroxyl (HNO) or nitric oxide (NO) demonstrated increased cytotoxicity toward human lung carcinoma cells compared to either aspirin or the parent nitrogen oxide donor. In addition, cytotoxicity was significantly lower in endothelial cells, suggesting cancer-specific sensitivity. To assess the chemotherapeutic potential of these new prodrugs in treatment of breast cancer, we studied their effect both in cultured cells and in a nude mouse model. Both prodrugs reduced growth of breast adenocarcinoma cells more effectively than the parent compounds while not being appreciably cytotoxic in a related nontumorigenic cell line (MCF-10A). The HNO donor also was more cytotoxic than the related NO donor. The basis for the observed specificity was investigated in terms of impact on metabolism, DNA damage and repair, apoptosis, angiogenesis and metastasis. The results suggest a significant pharmacological potential for treatment of breast cancer.

Citing Articles

Fifty Years of Diazeniumdiolate Research: A Tribute to Dr. Larry K. Keefer.

Kashfi K Crit Rev Oncog. 2023; 28(1):47-55.

PMID: 37824386 PMC: 11076142. DOI: 10.1615/CritRevOncog.2023048491.

The Chemical Biology of NO that Regulates Oncogenic Signaling and Metabolism: NOS2 and Its Role in Inflammatory Disease.

Miranda K, Ridnour L, Cheng R, Wink D, Thomas D Crit Rev Oncog. 2023; 28(1):27-45.

PMID: 37824385 PMC: 11318306. DOI: 10.1615/CritRevOncog.2023047302.

-Diazeniumdiolate Graminine in the Siderophore Gramibactin Is Photoreactive and Originates from Arginine.

Makris C, Carmichael J, Zhou H, Butler A ACS Chem Biol. 2022; 17(11):3140-3147.

PMID: 36354305 PMC: 9679993. DOI: 10.1021/acschembio.2c00593.

Chitosan as possible inhibitory agents and delivery systems in leukemia.

Zivarpour P, Hallajzadeh J, Asemi Z, Sadoughi F, Sharifi M Cancer Cell Int. 2021; 21(1):544.

PMID: 34663339 PMC: 8524827. DOI: 10.1186/s12935-021-02243-w.

Kinetics of Azanone (HNO) Reactions with Thiols: Effect of pH.

Smulik-Izydorczyk R, Debowska K, Rostkowski M, Adamus J, Michalski R, Sikora A Cell Biochem Biophys. 2021; 79(4):845-856.

PMID: 33950351 PMC: 8558164. DOI: 10.1007/s12013-021-00986-x.

References

Gallo O, Masini E, Morbidelli L, Franchi A, Vergari W, Ziche M . Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst. 1998; 90(8):587-96. DOI: 10.1093/jnci/90.8.587. View

Bandarage U, Chen L, Fang X, Garvey D, Glavin A, Janero D . Nitrosothiol esters of diclofenac: synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. J Med Chem. 2000; 43(21):4005-16. DOI: 10.1021/jm000178w. View

Masri F, Comhair S, Koeck T, Xu W, Janocha A, Ghosh S . Abnormalities in nitric oxide and its derivatives in lung cancer. Am J Respir Crit Care Med. 2005; 172(5):597-605. PMC: 2718532. DOI: 10.1164/rccm.200411-1523OC. View

Miranda K, Yamada K, Espey M, Thomas D, DeGraff W, Mitchell J . Further evidence for distinct reactive intermediates from nitroxyl and peroxynitrite: effects of buffer composition on the chemistry of Angeli's salt and synthetic peroxynitrite. Arch Biochem Biophys. 2002; 401(2):134-44. DOI: 10.1016/S0003-9861(02)00031-0. View

Keefer L . Nitric oxide (NO)- and nitroxyl (HNO)-generating diazeniumdiolates (NONOates): emerging commercial opportunities. Curr Top Med Chem. 2005; 5(7):625-36. DOI: 10.2174/1568026054679380. View

Hajri A, Metzger E, Vallat F, Coffy S, Flatter E, Evrard S . Role of nitric oxide in pancreatic tumour growth: in vivo and in vitro studies. Br J Cancer. 1998; 78(7):841-9. PMC: 2063136. DOI: 10.1038/bjc.1998.591. View

Dimmeler S, Haendeler J, Nehls M, Zeiher A . Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J Exp Med. 1997; 185(4):601-7. PMC: 2196141. DOI: 10.1084/jem.185.4.601. View

Pathi S, Jutooru I, Chadalapaka G, Sreevalsan S, Anand S, Thatcher G . GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. Mol Cancer Res. 2010; 9(2):195-202. PMC: 3069691. DOI: 10.1158/1541-7786.MCR-10-0363. View

Ruegg C, Dormond O, Mariotti A . Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. Biochim Biophys Acta. 2004; 1654(1):51-67. DOI: 10.1016/j.bbcan.2003.09.003. View

10.

Velazquez C, Chen Q, Citro M, Keefer L, Knaus E . Second-generation aspirin and indomethacin prodrugs possessing an O(2)-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studies. J Med Chem. 2008; 51(6):1954-61. DOI: 10.1021/jm701450q. View

11.

Keeble J, Moore P . Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol. 2002; 137(3):295-310. PMC: 1573498. DOI: 10.1038/sj.bjp.0704876. View

12.

Trifan O, Hla T . Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med. 2003; 7(3):207-22. PMC: 6741314. DOI: 10.1111/j.1582-4934.2003.tb00222.x. View

13.

DeMaster E, Redfern B, Nagasawa H . Mechanisms of inhibition of aldehyde dehydrogenase by nitroxyl, the active metabolite of the alcohol deterrent agent cyanamide. Biochem Pharmacol. 1998; 55(12):2007-15. DOI: 10.1016/s0006-2952(98)00080-x. View

14.

Fosslien E . Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 2000; 30(1):3-21. View

15.

Wink D, Feelisch M, Fukuto J, Chistodoulou D, Jourdheuil D, Grisham M . The cytotoxicity of nitroxyl: possible implications for the pathophysiological role of NO. Arch Biochem Biophys. 1998; 351(1):66-74. DOI: 10.1006/abbi.1997.0565. View

16.

LEAHY K, Koki A, Masferrer J . Role of cyclooxygenases in angiogenesis. Curr Med Chem. 2000; 7(11):1163-70. DOI: 10.2174/0929867003374336. View

17.

Allison M, Howatson A, Torrance C, Lee F, Russell R . Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med. 1992; 327(11):749-54. DOI: 10.1056/NEJM199209103271101. View

18.

Lopez B, Rodriguez C, Pribadi M, Cook N, Shinyashiki M, Fukuto J . Inhibition of yeast glycolysis by nitroxyl (HNO): mechanism of HNO toxicity and implications to HNO biology. Arch Biochem Biophys. 2005; 442(1):140-8. DOI: 10.1016/j.abb.2005.07.012. View

19.

Macnaughton W, Cirino G, Wallace J . Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci. 1989; 45(20):1869-76. DOI: 10.1016/0024-3205(89)90540-7. View

20.

Antman E, Bennett J, Daugherty A, Furberg C, Roberts H, Taubert K . Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007; 115(12):1634-42. DOI: 10.1161/CIRCULATIONAHA.106.181424. View